Skip to main content
SpringerLink
Log in

Kardiovaskuläre Outcome-Studien in der Diabetologie – ein Überblick

Trials on cardiovascular outcomes in diabetology

  • Aktuelles
  • Published:
Journal für Klinische Endokrinologie und Stoffwechsel Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Holman RR, Sourij H, Califf RM (2014) Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 383(9933):2008–2017. https://doi.org/10.1016/S0140-6736(14)60794-7

    Article  CAS  PubMed  Google Scholar 

  2. Meinert CL, Knatterud GL, Prout TE, Klimt CR (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19(suppl):789–830

    Google Scholar 

  3. Bethel MA, Sourij H (2012) Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice. Curr Cardiol Rep 14(1):59–69

    Article  PubMed  Google Scholar 

  4. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373(3):232–242

    Article  CAS  PubMed  Google Scholar 

  5. White WB, Zannad F (2014) Saxagliptin, alogliptin, and cardiovascular outcomes. N Engl J Med 370(5):484

    Article  PubMed  Google Scholar 

  6. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317–1326

    Article  CAS  PubMed  Google Scholar 

  7. Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P et al (2017) Pancreatic safety of sitagliptin in the TECOS study. Diabetes Care 40(2):164–170

    Article  PubMed  Google Scholar 

  8. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373(23):2247–2257

    Article  CAS  PubMed  Google Scholar 

  9. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311–322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834–1844

    Article  CAS  PubMed  Google Scholar 

  11. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, EXSCEL Study Group (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377(13):1228–1239. https://doi.org/10.1056/NEJMoa1612917

    Article  CAS  PubMed  Google Scholar 

  12. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128

    Article  CAS  PubMed  Google Scholar 

  13. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657

    Article  CAS  PubMed  Google Scholar 

  14. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. https://doi.org/10.1056/NEJMoa1615692

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinische Abteilung für Endokrinologie und Diabetologie, Medizinische Universität Graz, Auenbruggerplatz 15, 8036, Graz, Österreich

    Caren Sourij &  Harald Sourij

Authors
  1. Caren Sourij
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harald Sourij
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harald Sourij.

Ethics declarations

Interessenkonflikt

C. Sourij hat keine Interessenskonflikte. H. Sourij erhielt „unrestricted research grants“ von MSD, Böhringer Ingelheim, NovoNordisk, Sanofi und Astra Zeneca. Er ist beratend und als Sprecher für Astra Zencea, Böhringer Ingelheim, Eli Lilly, MSD, NovoNordisk und Sanofi tätig.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sourij, C., Sourij, H. Kardiovaskuläre Outcome-Studien in der Diabetologie – ein Überblick. J. Klin. Endokrinol. Stoffw. 10, 119–121 (2017). https://doi.org/10.1007/s41969-017-0013-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s41969-017-0013-4

Search

Navigation